News

The combination therapy did not demonstrate an improvement in best corrected visual acuity (BCVA) compared to intravitreal aflibercept injection monotherapy at 12 weeks, the primary endpoint of the

With the court’s ruling, Depomed expects market exclusivity until December 2025 for NUCYNTA ER, NUCYNTA and NUCYNTA oral solution (an unmarketed form of NUCYNTA).  Jim Schoeneck, President and CEO of Depomed,

The pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) is for patients with chronic hepatitis C virus (HCV) genotype 1 who failed treatment with DAAs, including therapy with an

The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in

The company, which has a global workforce of 42,300 in 75 countries, said around 500 of the job cuts would be in Denmark. Majority of job cuts will

Under the terms of the agreement, Genentech will obtain exclusive worldwide rights, except South Korea, to develop and commercialize HM95573. Hanmi will receive an initial upfront payment of

The companies have signed a collaboration and technology licence agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds in

Arrowhead will get $35m up front and will be eligible to receive up to $617m in milestone payments. Amgen will also invest $21.5m in Arrowhead common stock. royalties

Under the terms of the agreement, GSK will provide €35 million support over a four year period, and Oncodesign will use this funding to integrate the site and